EGFR and cancer: In the pan-cancer analysis, a decreased probability of overall survival (OS) and disease-specific survival (DSS) was found in amplified tumors in comparison with non-amplified ones (Supplementary Figure S2a,b), with EGFR, CDK4, MDM2, KRAS, and CCNE1-amplified tumors being those associated with a worse prognosis (Supplementary Figure S2c,d).